Splice Bio

Splice Bio

Private
Barcelona, BarcelonaHealthcare & Life Scienceshttps://www.splice.bio

Last Round

Series B

Jun 11, 2025

Total Funding Raised

$192M

Company Overview

SpliceBio is a biotechnology company focused on developing genetic medicines through Protein Splicing gene therapy, enabling the delivery of larger cargo genes and targeting a broader range of tissues to treat patients with incurable genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

protein splicinggene therapygenetic medicinesAAV vectorslarge gene deliveryStargardt diseasesplit-gene therapydual vector gene therapyinteinsinherited retinal diseaseseye gene therapyAAV payload capacityophthalmology gene therapyadeno-associated virus vectorsneurology gene therapyclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Splice Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Splice Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BJun 11, 2025
Series AFeb 16, 2022
SeedSep 15, 2020

Key People

Founding team and executive leadership

Miquel Vila-Perello

CEO

Executive Team

Splice Bio Investors

Notable investors and investment history

InvestorRounds
Asabys PartnersSeries B, Series A, Seed
UCB VenturesSeries A, Series B
Roche Venture FundSeries B
EQT Life SciencesSeries B
New Enterprise Associates (NEA)Series A, Series B
Ysios CapitalSeries B, Seed, Series A
Gilde HealthcareSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2025

    Proprietary platform based on Princeton University's Muir Lab technology.

  • Jun 11, 2025

    $135M round completed.

Splice Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Splice Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Splice Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona, Barcelona
Employee Range55
Year Founded2020
Last FundingJun 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.